Eli Lilly inks USD$2.75B AI drug deal with Insilico Medicine - Mugglehead Investment Magazine
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPdWhFNnpMTjhvT1ItOUZxUXgyQUlJdkZLRDRHdDctWE53NUFCc0wyLXAwamxXY1d3LWRVaFMzQnVkOFNXRjlRU3VkZzR4OXNtX0dkT0wyX1JCXzNEMUw3VVQwU1djdnRQLUNRdVJCeUtsMU05ZW41UktCeG9TQ01GR2JrQzhJM0VqWHlB?oc=5" target="_blank">Eli Lilly inks USD$2.75B AI drug deal with Insilico Medicine</a> <font color="#6f6f6f">Mugglehead Investment Magazine</font>
Could not retrieve the full article text.
Read on Google News: Generative AI →Google News: Generative AI
https://news.google.com/rss/articles/CBMiiwFBVV95cUxPdWhFNnpMTjhvT1ItOUZxUXgyQUlJdkZLRDRHdDctWE53NUFCc0wyLXAwamxXY1d3LWRVaFMzQnVkOFNXRjlRU3VkZzR4OXNtX0dkT0wyX1JCXzNEMUw3VVQwU1djdnRQLUNRdVJCeUtsMU05ZW41UktCeG9TQ01GR2JrQzhJM0VqWHlB?oc=5Sign in to highlight and annotate this article

Conversation starters
Daily AI Digest
Get the top 5 AI stories delivered to your inbox every morning.
More about
investment
AI Needs to Be Controlled Properly: Kyndryl CEO
Kyndryl is launching a new service to help companies manage AI agents and get better returns from their investment on the tech. Kyndryl CEO Martin Schroeter joins Tim Stenovec on “Bloomberg Tech.” (Source: Bloomberg)

AI Needs to Be Controlled Properly: Kyndryl CEO
Kyndryl is launching a new service to help companies manage AI agents and get better returns from their investment on the tech. Kyndryl CEO Martin Schroeter joins Tim Stenovec on “Bloomberg Tech.” (Source: Bloomberg)
Knowledge Map
Connected Articles — Knowledge Graph
This article is connected to other articles through shared AI topics and tags.





Discussion
Sign in to join the discussion
No comments yet — be the first to share your thoughts!